Creative Proteomics is highlighting its Ames test service for pharmaceutical developers, biotechnology companies, academic researchers and contract research organizations seeking early insight into the mutagenic potential of compounds. The service supports genetic toxicology programs by combining bacterial reverse mutation assays with flexible testing formats and expert data interpretation.
The Ames test evaluates whether a compound can induce gene mutations in specific bacterial tester strains. Creative Proteomics’ service portfolio includes Salmonella typhimurium and Escherichia coli strains, with formats such as Micro Ames, Ames MPF, Ames II and Mini Ames. These options are intended to support different project stages, sample availability, throughput requirements and research objectives.
The company also describes enhanced testing approaches using S9 metabolic activation systems. In bacterial reverse mutation testing, S9 provides an exogenous metabolic system that can help evaluate compounds whose mutagenic activity may depend on metabolic conversion. Testing with and without metabolic activation can provide complementary information about the parent compound and relevant metabolites.
For regulatory-oriented research, Creative Proteomics references OECD 471, ICH S2(R1), and related EMA and FDA guidance. Its OECD 471-aligned bacterial reverse mutation screening is presented for early compound evaluation, impurity and degradation-product assessment, and broader mutagenicity research involving pharmaceuticals, chemicals, agrochemicals, food ingredients, cosmetics and environmental samples.
The Ames test measures a specific bacterial gene-mutation endpoint. A positive or negative result should therefore be interpreted within the broader study context and does not, by itself, establish or exclude carcinogenicity in humans or fully characterize all forms of mammalian genotoxicity. Additional testing may be appropriate depending on the compound, study objective and applicable regulatory framework.
Creative Proteomics describes a workflow that includes tester-strain selection, metabolic activation, compound exposure, incubation, revertant-colony assessment, control comparisons, statistical analysis and reporting. Potential deliverables include raw data, colony counts, statistical results, publication-ready charts and expert interpretation.
Creative Proteomics’ broader capabilities span omics, bioinformatics and drug-research support. Its integrated analytical support for research teams provides a wider analytical context for projects requiring complementary workflows alongside genetic toxicology studies.
About Creative Proteomics:
Creative Proteomics provides analytical research services for pharmaceutical, biotechnology and academic customers. Its capabilities include proteomics, metabolomics, lipidomics, glycomics, bioinformatics, drug research and related scientific analysis. Services are provided for research use only and are not intended for diagnostic procedures.
Media Contact:
Contact Person: Melissa George
Email: contact@creative-proteomics.com
Phone: +1(631)593-0501
Website: creative-proteomics.com
Address: Shirley, NY, USA